SOLUTION / PUBLIC SOURCE RECORD
Zimmer & Peacock pioneers wearable biosensors for healthcare
- Published 2 October 2023; updated 23 March 2026; estimated reading time 3 minutes. Marked available; listed under Health and life science / Medtech and Technology / Artificial intelligence and machine learning.
- Zimmer & Peacock (ZP) develops wearable biosensor systems that focus on biochemical measures such as glucose, lactate, pH and potassium, rather than only physical activity measures. Biosensors convert a biological response into an electrical signal. The company says it can work with customers to develop sensors for additional needs and allow customer-built apps.
- ZP describes integrated continuous measurements plus AI-assisted data analysis as a way to provide more consistent metrics for clinical decision support and monitoring. The article discusses continuous glucose monitoring for type 1 and type 2 diabetes. It does not identify approved products, clinical evidence, measurement accuracy or regulatory status; the claimed health benefits should be treated as company positioning.
- ZP says it has developed 35 biosensors for varied applications and continues to work with R&D groups and industry. Soil health is another stated impact area, through spinoff AgriSenze AS, which the page links to a nitrate biosensor solution.
- The article cites a wearable-medical-device market forecast rising from USD 28.3 billion in 2021 to USD 197.1 billion by 2030; this is a historical forecast. It identifies healthcare, personal health/care, and food and beverage as demand drivers.
- Linked to SDG 3 (Good health and well-being).
- Contact: Even Zimmer, CEO, evenzimmer@zimmerpeacock.com. Company: ZIMMER & PEACOCK AS, Nedre vei 8, 3183 Horten, Norway; zimmerpeacock.com.